



Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF- β receptors

Trinh-Le-Vi Kieu, Léa Pierre, Valentin Derangère, Sabrina Perrey, Caroline Truntzer, Antoine Jalil, Sébastien Causse, Emma Groetz, Adélie Dumont, Laura Guyard, et al.

► To cite this version:

Trinh-Le-Vi Kieu, Léa Pierre, Valentin Derangère, Sabrina Perrey, Caroline Truntzer, et al.. Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF- β receptors. *Cell Death and Disease*, 2022, 13 (9), pp.758. 10.1038/s41419-022-05209-6 . hal-03972007

HAL Id: hal-03972007

<https://hal.science/hal-03972007>

Submitted on 29 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

ARTICLE OPEN



Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF- β receptors

Trinh-Le-Vi Kieu^{1,2,3}, Léa Pierre^{1,2}, Valentin Derangère^{1,4,5}, Sabrina Perrey^{1,2,3}, Caroline Truntzer^{1,4,5}, Antoine Jalil^{1,3,4}, Sébastien Causse^{1,2}, Emma Groetz^{1,3}, Adélie Dumont^{1,2}, Laura Guyard⁵, Laurent Arnould⁵ , Jean-Paul Pais de Barros^{3,6}, Lionel Apetoh^{1,3} , Cédric Rêbé^{1,5} , Emeric Limagne^{1,5}, Tony Jourdan^{1,3}, Laurent Demizieux^{1,2,3}, David Masson^{1,3}, Charles Thomas^{1,2,3} , François Ghiringhelli^{1,3,4,5} and Mickaël Rialland^{1,2,3}

© The Author(s) 2022

Metastatic breast cancer cannot be cured, and alteration of fatty acid metabolism contributes to tumor progression and metastasis. Here, we were interested in the elongation of very long-chain fatty acids protein 5 (Elovl5) in breast cancer. We observed that breast cancer tumors had a lower expression of Elovl5 than normal breast tissues. Furthermore, low expression of Elovl5 is associated with a worse prognosis in ER⁺ breast cancer patients. In accordance with this finding, decrease of Elovl5 expression was more pronounced in ER⁺ breast tumors from patients with metastases in lymph nodes. Although downregulation of Elovl5 expression limited breast cancer cell proliferation and cancer progression, suppression of Elovl5 promoted EMT, cell invasion and lung metastases in murine breast cancer models. The loss of Elovl5 expression induced upregulation of TGF- β receptors mediated by a lipid-droplet accumulation-dependent Smad2 acetylation. As expected, inhibition of TGF- β receptors restored proliferation and dampened invasion in low Elovl5 expressing cancer cells. Interestingly, the abolition of lipid-droplet formation by inhibition of diacylglycerol acyltransferase activity reversed induction of TGF- β receptors, cell invasion, and lung metastasis triggered by Elovl5 knockdown. Altogether, we showed that Elovl5 is involved in metastasis through lipid droplets-regulated TGF- β receptor expression and is a predictive biomarker of metastatic ER⁺ breast cancer.

Cell Death and Disease (2022)13:758; <https://doi.org/10.1038/s41419-022-05209-6>

INTRODUCTION

Breast cancer is the most frequent cancer in women with 2.26 million of new cases and the leading cause of cancer death in women with almost 685,000 deaths worldwide in 2020 [1]. The incidence and mortality of breast cancer steadily increase in the world with geographical and socioeconomic inequalities [2, 3]. Breast cancer is a heterogeneous disease with different subtypes defined by the following molecular classification: Luminal A and B (estrogen receptor-positive ER⁺), HER-2 positive (HER-2⁺ and ER⁺), basal-like (triple-negative breast cancer TNBC; ER[−], PR[−], and HER-2[−]) breast cancers [4–6]. A non-metastatic breast cancer has a good prognosis and the 5-year relative survival rate is ~90% in women [7–9]. On the other hand, the 5-year relative survival rate decreases to less than 30% for metastatic breast cancer with a median overall survival of ~3 years [8, 10]. Metastasis involves a multistep process resulting in the dissemination of cancer cells from the primary tumor to secondary sites [11]. The epithelial-to-mesenchymal transition (EMT) might be a critical mechanism for metastasis and is characterized by downregulation of epithelial

marker expression (i.e., E-cadherin or occludin) and upregulation of mesenchymal markers (i.e., vimentin or N-cadherin) [12].

Metabolic adaptation is a hallmark of cancers, and a reprogramming of fatty acid (FA) metabolism is observed in many cancer cells. Breast cancer is associated with quantitative and qualitative changes in FA composition [13]. Abolition of lipogenesis through inhibition of lipogenic enzyme activity decreases cancer cell proliferation and metastatic processes [13–16]. Exogenous fatty acids also contribute to the proliferation of breast cancer cells and the development of metastases [17, 18]. Modifications of cellular FA by desaturation and elongation are common in cancer cells, and alterations in the expression of these involved enzymes is described in breast cancer [13, 19]. Seven very long-chain fatty acid elongases (Elovl1–7) have been identified in the mouse, rat, and human genomes. These enzymes determine the rate of overall fatty acid elongation with substrate selectivity depending on carbon chain length and unsaturation degree; Elovl5 preferentially elongates C18 and C20 unsaturated FA [20].

¹Institut National de la Santé et de la Recherche Médicale (INSERM) UMR, 1231 Dijon, France. ²UFR Sciences de la Vie, Terre et Environnement, Université de Bourgogne Franche-Comté, Dijon, France. ³LipSTIC LabEx, Dijon, France. ⁴UFR des sciences de santé, Université de Bourgogne Franche-Comté, Dijon, France. ⁵Centre Georges François Leclerc, Dijon, France. ⁶Lipidomic Analytic Platform, Université de Bourgogne, Dijon, France. [✉]email: mickael.rialland@u-bourgogne.fr
Edited by Professor Gerry Melino

Received: 10 March 2022 Revised: 19 August 2022 Accepted: 23 August 2022

Published online: 02 September 2022

In this study, we were interested in the role of Elov5 in breast cancer progression. We developed different murine breast cancer models and showed that Elov5 controlled tumor growth and metastasis process through lipid-droplet-mediated regulation of TGF- β receptor expression.

RESULTS

Elov5 is downregulated in breast cancer, and a low expression of Elov5 is associated with poor clinical outcome

The analysis of Elov5 mRNA levels in the METABRIC dataset showed that the expression of Elov5 mRNA is downregulated in breast cancer tissues ($n = 957$ samples) compared to non-matched normal breast tissues ($n = 144$ samples) (Fig. 1A). We also found that Elov5 mRNA was differently expressed between the subtypes of breast cancer. Indeed, METABRIC dataset showed that ER⁺ breast cancer expressed higher Elov5 mRNA levels than Her2⁺ and TNBC (Fig. 1B). Then, we analyzed Elov5 mRNA expression in samples from 30 women with breast cancer for which we had breast tumor tissues and paired normal breast tissues (Supplementary Table S1). Overall, the analysis showed that the content of Elov5 mRNA was significantly reduced in breast cancer tissues compared to matched normal tissues (Fig. 1C). We confirmed with a H-score for the IHC Elov5 staining that the average expression of Elov5 was downregulated in breast cancer (T) tissue compared to adjacent normal (NT) breast tissue and was higher in ER⁺ breast cancer samples than in ER⁻ breast cancer tissues (Her2⁺ and TNBC) (Fig. 1D and Supplementary Table S2). From the METABRIC dataset, we found that a lower expression of Elov5 mRNA is associated with a shorter overall survival (OS) time for breast cancer patients without distinction of subtypes (Fig. 1E). In patients with ER⁺ cancer, low Elov5 mRNA expression was associated with a worse OS prognosis compared to patients with high Elov5 expression (Fig. 1F). No such association was observed for Her2⁺ and TNBC cancer patients (Fig. 1G, H).


Silencing of Elov5 expression inhibits breast cancer cell proliferation and tumor growth

To precise the role of Elov5 in breast cancer cell proliferation, we used mammary cell lines with different basal Elov5 expression levels, in which we further downregulated or overexpressed Elov5 expression (Supplementary Fig. S1A–G). Lipidomic analysis of mono- and polyunsaturated FA composition by Gas Chromatography-Mass Spectrometry (GC-MS) between Elov5-silenced breast cancer cells and their respective control breast cancer cells resulted in the accumulation of C16:1 n-7 and C18:3 n-6 FA (Supplementary Fig. S1H–J) whereas C16:1 n-7 and C18:3 n-6 content decreased in 4T1 cells stably overexpressing Elov5 (Supplementary Fig. S1K). We then showed that a reduction of Elov5 expression decreased the cell proliferation analyzed by crystal violet staining (Fig. 2A, B and Supplementary Fig. S2A). Conversely, a stable overexpression of Elov5 in 4T1 cells (Elov5-0 and Elov5-3) resulted in an increase of in vitro proliferation compared to control 4T1 (ctrl1 and ctrl3) (Fig. 2C). The colony-formation assays showed that Elov5 silencing (Fig. 2D, E) decreased the number of MCF-7 or 4T1 colonies whereas Elov5 overexpression increased the formation of 4T1 colonies (Fig. 2F). The loss of Elov5 expression did not trigger cell death (Supplementary Fig. S2B) but induced a cell cycle arrest in G0-G1 phase (Supplementary Fig. S2C) supporting the inhibition of proliferation in Elov5-depleted breast cancer cells. A previous publication reported a mitochondrial dysfunction of Elov5-silenced prostate cancer cells affecting their proliferation [21]. Unexpectedly, the transient or stable depletion of Elov5 expression in the MCF-7 breast cancer cells led to the increase of the basal and maximal mitochondrial oxygen consumption (Fig. 2G and Supplementary Fig. S2D). Next, we assessed the effect of

Elov5 overexpression in tumor growth by grafting 4T1 cells stably overexpressing Elov5 or control 4T1 cells in the fourth mammary fat pad of female Balb-c mice. Our results showed that Elov5 expression increased the 4T1 tumor growth (Fig. 2H). We also used the MMTV-PyMT mammary cancer mouse model, which mimics human luminal B breast cancer [22]. To evaluate the role of Elov5 invalidation in breast cancer progression, we crossed Elov5 full knockout female C57BL/6 mice with MMTV-PyMT male C57BL/6 mice. After the confirmation of Elov5 gene invalidation (Supplementary Fig. S2E, F), we found as expected that mammary tumor tissues from MMTV-PyMT;Elov5^{-/-} (hereafter termed Elov5^{-/-}) mice had a significantly increased in the percentage of C18:3 n-6 FA compared to mammary tumor tissues of MMTV-PyMT;Elov5^{+/+} (hereafter termed Elov5^{+/+}) (Supplementary Fig. S2G). We then monitored tumor growth until the sacrifice of the mice at 180 days of age; all female mice developed at least one mammary tumor at this time point. The surface of the aggregated tumor lesions at 180 days was lower in Elov5^{-/-} than in Elov5^{+/+} mice (Fig. 2I). However, we observed a slight delay in tumor onset in Elov5^{-/-} compared to Elov5^{+/+} mice which could explain the difference in tumor surface (Fig. 2J). Therefore, we determined the tumor growth rate in the 22 days starting from the detection of the first tumor. In these 22 days, the mean aggregated tumor surface increased 11.6-fold in Elov5^{+/+} mice and only 7.4-fold in Elov5^{-/-} mice (Fig. 2K and Supplementary Fig. S2H). To evaluate a clinical relevance of Elov5 expression in human breast tumor growth, we determined the breast tumoral zone with the lowest and with the highest Elov5 H-score for each patient, and we found that cancer cell proliferation analyzed by a Ki67 H-score is positively correlated with Elov5 H-score in the corresponding breast tumor lesion (Fig. 2L). Altogether these data show that Elov5 controlled proliferation and tumor growth in breast cancer.

Loss of Elov5 promotes the development of lung metastases

A weak expression of Elov5 is associated with a worse prognosis in breast cancer. However, the breast cancer aggressiveness is not dependent on the cancer cell proliferation since low expression of Elov5 inhibited proliferation (Fig. 2). Therefore, we investigated the role of Elov5 in metastasis which remains the main risk of death in breast cancer patients [23]. We observed that the Elov5^{-/-} mice developed more metastases on their lung surface than the Elov5^{+/+} mice (Supplementary Fig. S3A, B). The quantification of metastases area in H&E-stained sections from lungs using QuPath analysis confirmed that the area occupied by metastases relative to the total lung area was greater in Elov5^{-/-} than in Elov5^{+/+} mice (Fig. 3A). Moreover, mice transplanted with Elov5-overexpressing 4T1 cells in their mammary fat pad showed lower metastases counts on their lung surface and less lung area was invaded by metastases in comparison to control 4T1 tumor-bearing mice (Fig. 3B and Supplementary Fig. S3C, D). To further investigate the role of Elov5 in the metastatic process, we injected MCF-7 or 4T1 cells with different Elov5 expression levels in the tail vein, to partially mimic metastasis. As expected, we observed that stable downregulation of Elov5 in MCF-7 (shRNA Elov5) resulted in more metastases in the lungs of female NMRI-nude mice (Fig. 3C and Supplementary Fig. S3E). In contrast, tail vein injection of 4T1 cells stably overexpressing Elov5 in female Balb-c mice led to a decrease in the number of metastases and lung surface with metastases in comparison to control 4T1 cells (Supplementary Fig. S3F, G). To confirm the association of Elov5 expression and lymph node metastasis in breast cancer, we conducted an IHC analysis of patients with or without lymph node invasion (Table S3). The Elov5 H-score defined with QuPath analysis on breast cancer tissues was significantly higher in ER⁺ patients without metastases in lymph nodes (N0) than with metastases in lymph nodes (N1). No differences in the Elov5 H-score were observed between N0 and N1 status in patients with Her2⁺ or TNBC cancers (Fig. 3D and Supplementary Fig. S3H). Moreover, we confirmed that the Elov5



H-score is higher in ER⁺ patients (both N0 and N1) than in Her2⁺ or TNBC patients (Fig. 3E). These results demonstrate that a decrease in Elov15 expression correlates to lymph node invasion in ER⁺ breast cancers and promotes the formation of lung metastases in mouse breast cancer models.

Downregulation of Elov15 increases the invasiveness and expression of EMT markers

The metastatic process at the cellular level is associated with the acquisition of invasive properties and a mesenchymal phenotype [12]. Stable or transient Elov15 downregulation significantly

Fig. 1 Expression of Elov5 in women breast cancer patients. **A** Comparison of Elov5 mRNA expression in normal ($n = 144$) and breast cancer ($n = 957$) tissues in the METABRIC cohort. The p value obtained using a Wilcoxon rank test is indicated. **B** Expression of Elov5 mRNA in breast cancer subtypes (normal $n = 144$, ER⁺ $n = 712$, Her2⁺ $n = 55$, TNBC = 129) using METABRIC dataset. The P value was calculated using a Wilcoxon rank test. **C** Elov5 mRNA expression in tumor sections relative to paired normal tissues are reported as Log2 of fold change. The P value was calculated using a Wilcoxon matched paired-rank test. **D** Box and whisker plots showing H-score of Elov5 IHC staining in non-tumoral adjacent (NT) and tumoral (T) breast tissues from patients with different breast cancer subtypes. Median values are indicated with the horizontal line. The whiskers show the lowest and highest values. $P < 0.05$, $**P < 0.01$, $***P < 0.001$, and $****P < 0.0001$ and non-significant (ns) were obtained using a Wilcoxon rank test. Representative images are shown for each subtype with breast tumor tissues in red and normal adjacent tissues in blue. **E–H** Kaplan–Meyer curves for overall survival analysis in the METABRIC cohorts according to low (blue line) and high (red line) expression of Elov5 mRNA. P value was calculated using the log-rank Mantel–Cox test.

promoted invasiveness in low invasive MCF-7 cells (Fig. 3E, F). In 4T1 cells with high basal invasive properties, knockdown of Elov5 expression (siRNA Elov5) also increased cell invasion compared to control (siRNA ctrl) 4T1 cells (Fig. 3G), whereas Elov5 overexpression (Elov-0 and Elov-3) limited invasiveness of 4T1 cells in comparison to control (ctrl1 and ctrl3) 4T1 cells (Fig. 3H). Changes in cell morphology through actin cytoskeleton remodeling is critical for invasion. Therefore, we visualized actin fibers (F-actin) with FITC-conjugated phalloidin staining and found that suppression of Elov5 in 4T1 and MCF-7 cells induced a mesenchymal-like morphology, like TGF- β used as a positive control (Fig. 3I). Then, we analyzed by western blotting the expression of EMT markers which showed a decrease in the expression of epithelial markers (E-cadherin and occludin) and an increased expression of mesenchymal markers (vimentin and N-cadherin) in Elov5-silenced breast cancer cells (Fig. 3J, K). In contrast, overexpression of Elov5 in 4T1 cells (E0 and E3) reduced the expression of mesenchymal markers (vimentin and N-cadherin) and slightly increased the expression of epithelial markers (E-cadherin and occludin) (Fig. 3L). These data highlight that repression of Elov5 expression sustains invasiveness and EMT in breast cancer cells.


Elov5-regulated expression of TGF- β receptors controls cell proliferation and invasion

The transforming growth factor- β (TGF- β) pathway is a major contributor of EMT and metastasis. Thus, we aimed to investigate the expression of TGF- β receptors in breast cancer cells upon modulation of Elov5 expression. Silencing of Elov5 expression in both MCF-7 and 4T1 cells induced the expression of TGFBR1 and TGFBR2 mRNA (Fig. 4A, B and Supplementary Fig. S4A). Conversely, the stable overexpression of Elov5 in 4T1 cells (Elov5-0 and Elov5-3) decreased the expression of TGFBR1 and TGFBR2 mRNA (Supplementary Fig. S4B). We confirmed at the protein level that the expression of TGF- β receptor 1 (TGF β -R1) by immunofluorescence staining (Fig. 4C) and expression of TGF- β receptor 2 (TGF β -R2) by western blotting (Fig. 4D) were enhanced in Elov5-depleted breast cancer cells. Furthermore, we demonstrated an increase in TGF β -R1 and TGF β -R2 expression at the plasma membrane by flow cytometry analysis of breast cancer cells with suppressed Elov5 expression (Fig. 4E and Supplementary Fig. S4C) while stable overexpression of Elov5 reduced their exposure at the plasma membrane (Supplementary Fig. S4D). Moreover, we were able to show an increase of TGFBR1 and TGFBR2 mRNA expression in breast tumors from Elov5^{-/-} mice compared to tumors from Elov5^{+/+} (Fig. 4F). Given that TGF β -R1 and TGF β -R2 expression were upregulated in Elov5-silenced breast cancer cells, such cancer cells should present a higher activation of downstream signaling in response to TGF- β treatment. To evaluate the activation of the TGF- β pathway, we analyzed phosphorylation of smad2/3 (p-smad2/3) by western blotting. We showed that TGF- β 1 treatment (5 ng/ml) for 30 or 60 min in Elov5-silenced cancer cells induced a higher p-smad2/3 expression highlighting that the TGF- β pathway was more activatable (Fig. 4G and Supplementary Fig. S4E). It is noteworthy that there was an induction of p-smad2/3 with downregulation of Elov5 in untreated conditions suggesting the presence of TGF- β

in the extracellular microenvironment. We then evaluated the mRNA expression of the different TGF- β isoforms, and we found an increase in TGF- β 3 transcripts in Elov5-depleted MCF-7 and 4T1 cells (Supplementary Fig. S4F, G). To demonstrate the role of TGF- β receptors in Elov5-dependent cell invasion and proliferation, we inhibited TGF- β receptor activity with pharmacological drugs. The treatment with LY2157299 and LY2109761 prevented the increase of Elov5-depleted MCF-7 and 4T1 cell invasion compared to control cells (Fig. 4H, I and Supplementary Fig. S4H). Moreover, treatment with the inhibitors of TGF- β receptors (LY2157299 and LY2109761) alleviated the repression of proliferation induced by Elov5 silencing in breast cancer cells (Fig. 4J, K and Supplementary Fig. S4I). Collectively, these data suggest regulation of TGF- β receptor expression by Elov5.

Suppression of Elov5 drives DGAT1/2-dependent accumulation of lipid droplets

In order to evaluate the modification of lipid metabolism under the Elov5 regulation, we analyzed the expression of lipogenic and triacylglycerols (TAG) synthesis enzymes by western blotting. The Elov5 depletion in MCF-7 cells induced a lipogenic program characterized by a decrease of the inhibitory phosphorylation of ACC and an increase of Scd1 expression (Fig. 5A). Furthermore, we evaluated the expression of Diacylglycerol Acyltransferases (DGAT) 1 and 2 which participate in TAG synthesis, and found an increase in DGAT1 and DGAT2 expression in Elov5-silenced cancer cells (Fig. 5B and Supplementary Fig. S5A). We then determined the total FA content by GC-MS and TAG content by enzymatic assay in breast cancer cells. We observed that transient depletion of Elov5 in breast cancer cells using a siRNA for 48 h or its stable depletion by a shRNA in MCF-7 cells led to an intracellular accumulation of total FA (Fig. 5C) and TAG (Fig. 5D). Mammary tumor tissues from Elov5^{-/-} mice also harbored higher FA and TAG content compared to mammary tumor tissues from Elov5^{+/+} mice (Fig. 5E, F). In addition, we analyzed TAG content in breast tumor tissues in which Elov5 expression was lower compared to their paired non-tumoral counterparts from patients with different cancer subtypes (Fig. 5G). The TAG content was significantly higher in breast tumor tissues than in paired non-tumoral tissues from patients with ER⁺ and Her2⁺ breast cancer; a non-significant increase in TAG concentration was also observed in tumor tissues of the TNBC subtype compared to paired normal tissues (Fig. 5G). Moreover, the average TAG concentration was different between subtypes with the highest concentration in the ER⁺ subtype (Fig. 5G). TAG are a major neutral lipid constituent of lipid droplets (LD), storing the excess of FA, and the final step of their synthesis depends on DGAT1/2 activity [24]. We showed that the breast cancer cells (MCF-7 and 4T1) with depletion of Elov5 expression increased their content of intracellular LD (green dots in the cells) detected by fluorescence microscopy using Bodipy 493/503 or Nile red staining (Fig. 5H and Supplementary Fig. S5B–D). In accordance, the amount of total fatty acids in lipid droplets isolated from Elov5-silenced MCF-7 cells is increased compared to control MCF-7 cells (Fig. 5I). The total fatty acids in LD from control MCF-7 cells contained 81.6% of SFA, 16.2% of MUFA and 2.2% of PUFA whereas 95.7% of SFA, 3.4% of MUFA and 0.9% of PUFA are found in LD from



Elov5-silenced MCF-7 cells (Supplementary Table S4 and Supplementary Fig. S5E–G). On the contrary, the depletion of Elov5 expression did not drastically change the cellular SFA (62.8% vs 62.1%), MUFA (31.4% vs 29.4%; $P < 0.05$) and PUFA (7.1% vs 7.7%; $P < 0.05$) proportion compared to the control MCF-7 cells (Supplementary Table S4). Interestingly, the cellular content in the C24:5

and C24:6–C30:6 fatty acids increased in Elov5-depleted MCF-7 cells (Supplementary Fig. S5G). Among the ≥ 24 PUFA, their percentages decreased in LD from Elov5-silenced MCF-7 cells except for the C26:6 (Supplementary Fig. S5G). The effect of Elov5 invalidation on LD content in mammary tumors was investigated, and the analysis showed more Oil Red O stained-positive cancer cells in mammary

Fig. 2 Cell proliferation and breast tumor growth under the control of Elov5 expression. **A–C** Proliferation of Elov5-depleted (**A**, **B**) and Elov5-overexpressing cancer cells (**C**) evaluated by crystal violet staining. Error bars represent the mean \pm SD of independent experiments ($n = 3$ (**A**), $n = 4$ (**B**) and $n = 3$ (**C**)) with $*P < 0.05$, $**P < 0.01$ and $***P < 0.001$ using a one-way ANOVA analysis with Tukey test (**B**, **C**) and a Student's t test at each time point for (**A**). **D–F** Colony-formation assay analyzed by crystal violet staining. Error bars represent the mean \pm SD of three independent experiments with $*P < 0.05$, $**P < 0.01$, $***P < 0.001$ and $****P < 0.0001$ using a Student's t test (**D**, **E**) or one-way ANOVA analysis with Tukey test (**F**). **G** Oxygen consumption rate measured with Seahorse XFe96 analyzer in Elov5-depleted MCF-7 cells. Error bars represent the mean \pm SD with $*P < 0.05$ according to Student's t test. **H** Tumor growth of Elov5-overexpressing 4T1 (Elov5-0 and Elov5-3) and control 4T1 (ctrl1 and ctrl3) cells injected in the mammary fat pad of female Balb-c mice ($n = 10$ per group). Statistical significance $****P < 0.0001$ was calculated for Elov5 and ctrl groups on day 23 using a one-way ANOVA with Tukey's multiple comparison test. **I** Aggregated tumor surface analysis in MMTV-PyMT;Elov5^{+/+} (Elov5^{+/+}) and MMTV-PyMT;Elov5^{-/-} (Elov5^{-/-}) 6-month-old mice. Dots indicate the values of the cumulative surface of mammary tumor lesions for each individual mouse. Histograms and error bars indicate the mean \pm SEM with $*P < 0.05$ according to a Mann–Whitney test. **J** Kaplan–Meier curves of tumor-free survival percentage in PyMT-Elov5^{+/+} ($n = 23$) and PyMT-Elov5^{-/-} ($n = 20$) mice. A log-rank (Mantel–Cox) statistical test was used. **K** Tumor growth analysis in MMTV-PyMT;Elov5^{+/+} (Elov5^{+/+}, $n = 13$) and MMTV-PyMT;Elov5^{-/-} (Elov5^{-/-}, $n = 15$) mice. Values used are the cumulative surface of tumors per mice. Curves and error bars represent the mean \pm SEM with $*P < 0.05$ according to Student's t test calculated for each time point. **L** Analysis of Ki67 H-score according to the lowest and highest values of Elov5 H-score from tumor tissues of breast cancer patients. Each line links the lowest and highest value of Elov5 H-score from the same patient. The P value was obtained using a paired Student's t test. Representative images of Elov5 and Ki67 IHC with the corresponding high (1) and low (2) H-score region.

tumors of Elov5^{-/-} mice compared to the Elov5^{+/+} mice (Fig. 5J and Supplementary Fig. S5H). Finally, to explore the role of DGAT isoforms in LD formation in an Elov5-dependent manner, we inhibited DGAT1 and DGAT2 activity with pharmacological agents A922500 (DGAT1i) and PF-06424439 (DGAT2i) respectively and observed a decrease in LD accumulation in Elov5-depleted breast cancer cells treated with the DGAT inhibitors analyzed by fluorescence microscopy or flow cytometry (Fig. 5K and Supplementary Fig. S5I–N). Altogether, the data highlight the role of Elov5 in DGAT1/2-dependent LD formation.

Elov5 extinction-induced lipid droplets regulate the expression of TGF- β receptors through Smad2 acetylation

To further investigate the functions of LD in Elov5-dependent effects, we first analyzed levels of TGF- β receptors at the plasma membrane of breast cancer cells lacking Elov5 expression and exposed to DGAT inhibitors. Treatments with inhibitors of DGAT1 (A922500, DGAT1i) and DGAT2 (PF-06424439, DGAT2i) activity for 48 h were able to counteract the increase of plasma membrane TGF β -R1 and TGF β -R2 levels in Elov5-depleted breast cancer cells (Fig. 6A, B and Supplementary Fig. S6A). Similarly, preventing LD accumulation by A922500 and PF-06424439 for 48 h abrogated the induction of TGFBR1 and TGFBR2 mRNA expression in MCF-7 and 4T1 cells without Elov5 expression (Fig. 6C, D and Supplementary Fig. S6B). LD are a reservoir of substrates for fatty acid oxidation contributing to acetyl-CoA production [24]. Thus, we showed that silencing of Elov5 expression in MCF-7 cells led to increase of acetyl-CoA levels which is reversed by inhibition of DGAT1 and DGAT2 activity (Fig. 6E). Moreover, acetyl-CoA is a source of acetyl for post-translational Smad2 acetylation which activates its signaling [15]. Therefore, we analyzed Smad2 acetylation in MCF-7 cells with Elov5 suppression (shRNA Elov5) and found an increase of acetylated Smad2 content compared to control (shRNA control) MCF-7 cells (Fig. 6F). Furthermore, we showed that DGAT1 inhibition suppressed Smad2 acetylation induced by Elov5 downregulation (Fig. 6G). We postulated that Smad2 regulates the expression of TGF- β receptors due to its acetylation. Thus, the inhibition of Smad2 expression using siRNA transfection (Supplementary Fig. S6C) in Elov5-silenced MCF-7 cells counteracted induction of TGF- β receptor expression mRNA (Fig. 6H) and protein (Supplementary Fig. S6D). Overall, the data support the role of Smad2 in the regulation of TGF- β receptor expression through its acetylation.


Elov5 loss-dependent lipid-droplet accumulation promotes EMT, cell invasion, and lung metastasis

We evaluated the impact of LD reduction on the expression of EMT markers in breast cancer cells with Elov5 knockdown.

A mesenchymal phenotype with an upregulation of vimentin and downregulation of epithelial markers (E-cadherin and occludin) was obtained in breast cancer cells with stable or transient silencing of Elov5 expression as assessed at 48 h by western blotting (Fig. 7A) and RT-qPCR (Fig. 7B) while the treatment with DGAT inhibitors (DGAT1i and DGAT2i) reversed the EMT triggered by Elov5 extinction in breast cancer cells. Furthermore, we clearly confirmed that ablation of Elov5 expression with siRNA or shRNA in breast cancer cells inhibited cell proliferation (Supplementary Fig. S7A–C) and promoted cell invasion (Fig. 7C, D and Supplementary Fig. S7D). Nevertheless, the prevention of LD accumulation using DGAT inhibitors (DGAT1i and DGAT2i) in Elov5-depleted 4T1 and MCF-7 cells restored cell proliferation (Supplementary Fig. S7A–C) and decreased cell invasion (Fig. 7C, D and Supplementary Fig. S7D). To determine the role of Elov5 downregulation-induced LD accumulation in lung metastasis, we pre-treated shRNA ctrl or shRNA Elov5 MCF-7 cells with DGAT1 inhibitor (DGAT1i, 10 μ M) or vehicle (DMSO) for 24 h and then injected DGAT1i-treated MCF-7 cells in the tail vein of female Nude NMRI mice. Lungs were collected 35 days after injection of MCF-7 cells, and we confirmed that shRNA Elov5 MCF-7 cells led to the development of more metastases in lungs compared to shRNA ctrl MCF-7 (Fig. 7E and Supplementary Fig. S7E). However, the repression of LD accumulation by DGAT1i loading in shRNA Elov5 MCF-7 reduced the number of lung metastases (Fig. 7E and Supplementary Fig. S7E). Collectively, the data demonstrate that LD accumulation induced by Elov5 downregulation controls TGF- β receptor upregulation and drives metastasis.

DISCUSSION

In this study, we demonstrated a role of Elov5 in breast cancer growth and metastasis through the expression of TGF- β receptors, mediated by the storage of fat in lipid droplets. Our results showed that the downregulation of Elov5 expression inhibited the proliferation of breast cancer cells and reduced mammary tumor growth in murine models, which is consistent with a recent publication on prostate cancer [21]. Indeed, the depletion of Elov5 expression in prostate cancer cells led to inhibition of cell proliferation and metastasis [21]. Interestingly, we demonstrated that the formation of metastases and metastasis-associated features (cell invasion, TGF- β receptor expression and EMT) in breast cancer models were promoted by dampening Elov5 expression. In contrast, overexpression of Elov5 in murine 4T1 cells decreased the development of lung metastases. The data obtained from breast cancer patients confirmed a relationship between Elov5 expression and metastasis. A significant



downregulation of *Elov5* expression was observed in patients with metastatic ER⁺ breast cancers (N1) compared to non-metastatic ER⁺ breast cancers (N0). We did not find any differences in *Elov5* expression between patients with metastatic Her2⁺/TNBC breast cancers (N1) compared to non-metastatic

Her2⁺/TNBC breast cancers (N0). Of note, *Elov5* expression in patients with an N0 status is already much lower in Her2⁺ and TNBC breast cancer tissues compared to ER⁺ breast cancer tissues and is closer to the downregulated *Elov5* expression in ER⁺ breast cancer tissues from patients with N1 status. It is reported that


Fig. 3 **Elovl5 regulates metastasis, cell invasion, and expression of EMT markers.** **A–C** QuPath analysis for quantification of lung surface with metastases in 6-month-old female MMTV-PyMT;Elovl5^{+/+} (Elovl5^{+/+}) and MMTV-PyMT;Elovl5^{-/-} (Elovl5^{-/-}) mice (**A**), in lungs of female Balb-c mice with fat pad injection of Elovl5-overexpressing (Elovl5-0 and Elovl5-3) or control (ctrl1 and ctrl3) 4T1 cells (**B**), in lungs of female NMRI-nude mice with tail vein injection of shRNA Elovl5 or shRNA control (ctrl) MCF-7 (**C**). Representative images of H&E staining are shown. Data represent the mean \pm SEM. **D** Box and whisker plots showing H-score for Elovl5 IHC staining in breast cancer tissues of different subtypes (ER⁺, Her2⁺, and TNBC) from women patients with lymph node invasion (N1) or without invasion (N0). Median values are indicated with the horizontal line. The whiskers show the lowest and highest values. **E, F** Fold change of cell invasion for MCF-7 cells with stable (shRNA Elovl5) or transient (siRNA Elovl5) silencing of Elovl5 expression compared to respective control (shRNA ctrl or siRNA ctrl) MCF-7 cells. Invasive MCF-7 cells were stained with crystal violet for quantification. Histograms and error bars represent the mean \pm SD. **G** Cell invasion analysis for Elovl5-silenced 4T1 cells (siRNA Elovl5) and non-targeting siRNA (siRNA ctrl). Histograms and error bars represent the mean \pm SD. **H** Cell invasion index for Elovl5-overexpressing (Elov-0 and Elov-3) or control (ctrl1 and ctrl3) 4T1 cells. Data are represented as mean \pm SD. **I** Fluorescence staining of actin fibers with FITC-phalloidin in 4T1 and MCF-7 cells treated for 48 h with Elovl5 and non-targeting (ctrl) siRNA. Nuclei were counterstained with Hoechst. TGF- β treatment is used as a positive control for EMT. **J–L** Analysis of EMT markers by western blotting in Elovl5-silenced MCF-7 and Elovl5-overexpressing 4T1 cells. Images are representative of at least two independent experiments. ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, and non-significant (ns) were calculated using Mann–Whitney test (**A, C, D**), Student's *t* test (**E, F, G**), Kuskall–Wallis analysis with Dunn's test (**B**) and one-way ANOVA analysis with Tukey's test (**H**).

more than 75% of breast cancer deaths are caused by metastases [23]. Therefore, the correlation between a low expression of Elovl5 and a worse prognosis in patients with ER⁺ breast cancers could be explained by the fact that metastasis is promoted by Elovl5 silencing. In contrast, low expression of Elovl5 is not associated with a worse prognosis in Her2⁺ and TNBC patients. The Elovl5 expression as a prognostic biomarker in Her2⁺ and TNBC patients using the METABRIC database must be carefully interpreted since the analysis was performed on small TNBC and Her2⁺ cohorts (only 55 TNBC and 129 Her2⁺ patients). Moreover, we cannot exclude that Elovl5 interacts with a peculiar oncogenic pathway according to the breast cancer subtype and modifies the tumor cell secretome which might create a distinct microenvironment for tumor growth and metastasis.

TGF- β signaling exerts ambivalent properties in cancer with tumor suppressive effects at early stages and pro-metastatic action at a later stage [25]. TGF- β signaling has the ability to induce cell cycle arrest and/or apoptosis as well as to promote EMT and cell invasion in cancer cells, including breast cancer cells [26, 27]. Active TGF- β elicits its biological effects by binding to serine/threonine kinase TGF- β receptors (TGF- β -R) 1 and 2 directly or with the help of the accessory TGF- β -R3. Binding of TGF- β on the receptor complex triggers TGF- β -R2-induced transphosphorylation and activation of TGF- β -R1. Then, the canonical TGF- β transduction signal depends on TGF- β -R1-mediated phosphorylation of Smad2 and Smad3. The phospho-Smad2/3 heterodimer complex interacts with Smad4 for nuclear translocation of the heterotrimeric complex which runs a transcriptional program [25]. We demonstrated an increase in the expression of TGF- β isoforms and receptors in breast cancer cells lacking Elovl5 expression. Furthermore, Elovl5 depletion induced an increase in phospho-Smad2/3 content suggesting activation of the TGF- β pathway, and anti-proliferative and pro-metastatic effects of TGF- β signaling which were reversed by the inhibitors of TGF- β -R1 and TGF- β -R2. Metabolic adaptations are triggered during activation of the TGF- β pathway leading to an increase of mitochondrial oxygen consumption [28–30]. Thus, it is not surprising to observe an induction of the mitochondrial oxygen consumption in Elovl5-silenced breast cancer cells. Drugs against TGF- β signaling might offer a therapeutic response to cancer cell dissemination, and several inhibitors of the TGF- β pathway are tested for clinical evaluation [31]. However, the ambivalent role of TGF- β requires a precise selection of eligible patients with advanced breast cancer. Furthermore, dosing of anti-TGF- β signaling drugs must be personalized due to possible cardiac and cutaneous side effects [31, 32]. Elovl5 expression might be a predictive biomarker and help to determine eligible recipients of anti-TGF- β signaling therapy.

Alteration of lipid metabolism contributes to cancer progression and pre-clinical studies demonstrated the rationale of targeting lipid metabolism [13, 33, 34]. Elongation of fatty acid is

under the control of seven fatty acid elongases (Elovl) and expression of Elovl1 or Elovl6 is increased in breast cancer tissues [19]. Yamashita et al. also described the increase of Elovl5 mRNA expression in breast cancer tissues while they did not find any changes in protein levels of Elovl5 in IHC staining comparing breast tumors to normal paired tissues [19]. In our study, we were able to show a decrease of Elovl5 expression by RT-qPCR as well as by IHC staining in breast cancer tissues. A consequence of Elovl5 downregulation is an accumulation of LD in breast cancer cells which controlled their proliferation and invasion. The increase in the total FA and TAG content in breast cancer cells upon a depletion of Elovl5 was consistent with an activation of lipogenesis and LD formation. The main primary product of de novo lipogenesis is the saturated C16:0 FA which drastically increased in LD from Elovl5-silenced MCF-7 and can accumulate as C16:0-TAG protecting the cells from lipotoxicity [35]. The blockade of Elovl5-dependent elongation of fatty acids in breast cancer cells also induced an accumulation of C24:6-30:6 FA in the cellular FA fraction. The elongation of the C30:6 n-3 FA by Elovl4 led to the biosynthesis of C32:6-C34:6 and to their newly identified di-hydroxylated derivatives (elovanoids) [36]. The Elovl4 silencing-dependent decrease of C32:6 and C34:6 fatty acids triggered a reduction of lipid-droplet number in neuroblastoma cells while the accumulation of LD is associated with a better prognosis [37]. However, the increase of LD abundance is more frequently correlated with an aggressive cancer [38–41] and breast cancer cell lines show an increasing trend in LD content when going from the non-malignant MCF10A cells, to the intermediately aggressive MCF-7 cells to the highly aggressive MDA-MB-231 cells [42]. In accordance with these observations, we demonstrated that the LD accumulation in breast cancer cells is essential for the Elovl5 silencing-mediated promotion of EMT and invasion since a repression of LD formation by a blockade of DGAT1 or DGAT2 activity reversed the induction of EMT and cell invasion. These results highlighted that DGAT1 or DGAT2 have nonredundant properties and play a key role in LD biogenesis. Interfering with exogenous lipid uptake or lipogenesis also results in a decrease of LD abundance and affects the migratory and invasive properties of cancer cells [43–45]. Interestingly, the prevention of LD accumulation in Elovl5-silenced MCF-7 cells by a treatment with DGAT1 inhibitor reduced lung metastases in mice highlighting a therapeutic role of anti-lipid-droplet drugs against breast cancer metastasis. Moreover, LD are able to manage cell lipotoxicity and are a reservoir of FA for acetyl-CoA production during fatty acid oxidation [46]. Thus, we indicated that Elovl5-depleted breast cancer cells increased their mitochondrial oxygen consumption and contained more acetyl-CoA while the abrogation of LD formation by DGAT inhibitors deprived acetyl-CoA levels. The availability in acetyl-CoA contributes to the induction of TGF- β signaling through Smad2 activation by



acetylation, impacting EMT and metastasis [15, 44] and this is in line with our data indicating that LD induced by downregulation of Elov5 expression mediated upregulation of EMT and cell invasion. Finally, we evidenced that Smad2 acetylation also regulates the expression of TGF- β receptors since silencing of

Smad2 expression in Elov5-depleted MCF-7 cells prevented their overexpression.

This work suggests that treatment with DGAT inhibitors could block LD formation and the subsequent TGF- β signaling through repression of TGF- β receptor expression in Elov5-depleted breast

Fig. 4 **Elov15 modulates the expression of TGF- β receptors.** **A, B** Analysis of TGFBR1 and TGFBR2 mRNA expression at 24 h by RT-qPCR in Elov15-silenced MCF-7 cells by shRNA (**A**) and siRNA (**B**) relative to control shRNA or siRNA-treated MCF-7 cells. Histograms and error bars represent the mean \pm SD of three independent experiments. **C** Immunofluorescence staining of TGF- β receptor 1 (TGF- β -R1) in Elov15-silenced MCF-7 and 4T1 cells compared to a control siRNA or shRNA at 48 h. Nuclei are stained with Hoechst. Images are representative of three independent experiments. **D** Analysis of TGF- β receptor 2 (TGF- β -R2) in control and Elov15-silenced MCF-7 and 4T1 cells at 48 h by western blotting. Images are representative of three independent experiments. **E** Analysis of TGF- β receptor 1 and 2 expression at 48 h by flow cytometry in Elov15-targeting shRNA and control shRNA-treated MCF-7 cells. Values are the fold change in the mean of fluorescence intensity (MFI) of shRNA Elov15 cells relative to shRNA control cells. Histograms and error bars represent the mean \pm SD of four independent experiments. **F** Analysis of TGF- β receptor 1 and 2 expression by RT-qPCR in tumors from 140 days-old MMTV-PyMT;Elov15^{+/+} (Elov15^{+/+}; $n = 11$) and MMTV-PyMT;Elov15^{-/-} (Elov15^{-/-}; $n = 20$) mice. Data are expressed as the mean \pm SEM. **G** Analysis of Smad2/3 phosphorylation (p-Smad2/3) and total Smad2/3 expression in Elov15-silenced MCF-7 cells treated with TGF- β 1 (5 ng/ml) for the indicated times by western blotting. **H, I** Analysis of cell invasion for Elov15-depleted MCF-7 cells using shRNA (**H**) or transient siRNA (**I**) against Elov15 relative to MCF-7 cells treated with a control shRNA or siRNA (ctrl). Histograms and error bars represent the mean \pm SD of three independent experiments. Representative images are shown. **J, K** Analysis of proliferation by crystal violet staining in Elov15-depleted MCF-7 cells using an shRNA (**J**) or siRNA (**K**) against Elov15 relative to MCF-7 cells treated with a control shRNA or siRNA (ctrl). Histograms and error bars are expressed as the mean \pm SD of three independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ and non-significant (ns) were calculated using Student's t test (**A, B, E, F**) and one-way ANOVA analysis with Tukey's test (**H, I, J, K**).

cancer cells. As we discussed above, drugs targeting components of TGF- β signaling (i.e., TGF- β isoforms or TGF- β receptors) have an interesting potential against metastasis. However, the use of DGAT inhibitors might also improve the efficacy of anti-cancer drugs for the treatment of patients with a high risk of metastases associated to low levels of Elov15 by suppressing the resistance or buffering of these anti-cancer drugs by LD [47–49].

In conclusion, we demonstrate the role of Elov15 in breast cancer cells through a regulation of lipid-droplet content and expression of TGF- β receptors (Fig. 8). Furthermore, this study proves to be very interesting from a clinical perspective by suggesting a predictive potential of Elov15 expression as prognosis marker in the risk of development of metastases in patients with breast cancer and by describing a therapeutic potential for drugs preventing the formation of lipid droplets in cancer cells.

MATERIALS AND METHODS

Cell culture

Human adenocarcinoma MCF-7 (HTB-22-ATCC), MDA-MB-231 (HTB-26-ATCC), mouse 4T1 mammary carcinoma (CRL-2539-ATCC) and mouse NMuMG mammary cystadenoma (CRL-1636-ATCC) cell lines were used within the first 25 passages and tested for mycoplasma contamination (Lonza, Mycoalert Detection Kit, and Mycoalert Assay Control set). MDA-MB-231 and 4T1 cell lines were maintained in RPMI supplemented with 2 mM L-glutamine, 10% heat-depleted FBS, and antibiotics (Penicillin, streptomycin, and amphotericin B). MCF-7 and NMuMG cell lines were maintained in DMEM supplemented with 2 mM L-glutamine, 10% heat-depleted FBS, and antibiotics (Penicillin, streptomycin, and amphotericin B). Cells were grown in a humidified 5% CO₂ incubator at 37 °C.

Lentivirus production and MCF-7 cell line transduction

The pLKO.5-puro lentiviral vectors expressing a control shRNA (SHC202) or an Elov15-targeting shRNA (TRCN0000317892) were purchased from Sigma-Aldrich. Lentivirus was produced in HEK293T cells by transfection using Lipofectamine 2000 transfection reagent (ThermoFisher Scientific) of VSV-G envelope and PAX2 packaging vectors (Addgene). Lentivirus was collected 48 h after transfection for transduction of MCF-7 cells with 8 μ g/ml of polybrene (Sigma-Aldrich). After 2 days, transduced MCF-7 cells were selected with 2 μ g/ml puromycin (Fisher Scientific) to establish a control MCF-7 cell line or cell line with a stable Elov15 knockdown.

Elov15-overexpressing 4T1 cell line

Linearized empty pcDNA3.1 or pcDNA3.1 encoding the ORF of the murine Elov15 gene sequence (Genscript) were transfected into 4T1 cells using Lipofectamine 2000 transfection reagent (ThermoFisher Scientific) according to the manufacturer's protocol. Two days post transfection, non-clonal 4T1 cell lines that have stably integrated the plasmids were selected using 600 μ g/ml G418 sulfate (Euromedex).

RNA interference and treatments with inhibitors

Cells were reverse-transfected using Lipofectamine[™] RNAiMAX transfection reagent (ThermoFisher Scientific) with non-targeting siRNA (#4390846; Dharmacon), siRNA targeting human ELOVL5 (#s34075; Dharmacon), mouse ELOVL5 (#s87101; Dharmacon) or human smad2 (#s8397; Dharmacon) according to the manufacturer's instructions. Treatments with 10 μ M A922500 (Sigma-Aldrich), 10 μ M PF-06424439 (Sigma-Aldrich), 1 μ M LY2157299 (Selleck) and 1 μ M LY2109761 (Sigma-Aldrich) were performed in complete culture medium. Breast cancer cells were incubated with 5 ng/ml recombinant human TGF- β 1 (Miltenyi Biotec) in complete cell culture medium for the indicated times.

Total fatty acid analysis by gas chromatography-mass spectrometry (GC-MS)


Cell lines and tissue samples were homogenized, and lipids were extracted in 1 ml of ethanol/butylated hydroxytoluene (50 mg/ml); 60 μ l of 10 M potassium hydroxide, and 25 μ l of SI-internal standard (#SI S20-040; CDN Isotopes-Cayman) were added to the prepared-suspensions followed by saponification at 56 °C for 45 min. The aqueous phase was collected after the addition of 1 ml of 1.2 M hydrochloric acid and 3 ml of hexane. This was evaporated in a vacuum dry centrifuge at 100 °C, 2200 $\times g$. The dry residues were resuspended in 10% v/v N, N-diisopropylethylamine, 10% v/v pentafluorobenzyl bromide diluted in acetonitrile and incubated at 37 °C for 30 min to obtain pentafluorobenzyl esters. In all, 1 ml water and 2 ml hexane were used to support the esters extraction. The hexane phase was collected and evaporated with liquid nitrogen. The fatty acid ester pellets were solubilized in hexane, and 1 μ l was injected into a GC-MS system (#7890A Gas Chromatograph, #7683 injector, #5975C Mass Selective Detector; Agilent Technologies) in pulsed split mode by using fused silica capillary column (#HP-5MS; Agilent Technologies). GC-MS running-mode contained helium gas with a flowrate at 1.8 ml/min, injector temperature at 250 °C, pulsed split 10, the oven temperature was set at 140 °C for 1 min and then increased at a rate of 5 °C/min, then left at 300 °C for 7 min. The machine was set in negative chemical ionization mode, in the presence of methane as the reactant gas, with the temperature of ion source and quadrupole set at 150 °C. All the experimental steps were performed in glass-based containers. The FAs were first normalized using the closest internal standard by relative ratios using MassHunter and Qualitative software (Agilent Technologies). These FAs were then normalized to the total cell counts and the protein concentration from the initial sample.

Lipid-droplet isolation

To perform the lipidomic analysis on lipid droplet, MCF-7 cells were washed and harvested. After normalization of each sample by cellular counting, the lipid droplets were extracted by using lipid-droplet isolation kit (MET-5011; Cell Biolabs) according to the manufacturer's instructions. Floating lipid-droplet samples were collected for further lipidomic analysis.

Triacylglycerol (TAG) quantification

Cells and tissue samples were homogenized in one volume of methanol. Four volumes of dimethoxymethane were added, and the samples were continuously vortexed for 1 h. The organic solvents were evaporated under



N2 flow, and TAG were resuspended in CHCl₃-2% v/v Triton X-100. After CHCl₃ evaporation, deionized water was added to the Triton X-100 and TAG solution before TAG quantification using a Triglycerides FS enzymatic assay kit (Diagnosis systems) according to the manufacturer's instruction. TAG content was normalized to the protein content of the initial sample, obtained by BCA assay quantification.

Acetyl-CoA quantification

Total cell lysates were collected and deproteinized using the Deproteinization kit (#ab204708; Abcam). Intracellular Acetyl-CoA content was determined using the Acetyl-CoA assay kit (#PicoProbe ab87546; Abcam), following the manufacturer's instructions. Acetyl-CoA concentration was normalized to the protein content of the corresponding samples.

Fig. 5 Elov15 downregulation increases lipid-droplet abundance. **A** Expression of lipogenic enzymes analyzed by western blotting in Elov15-silenced MCF-7 cells. **B** Expression of DGAT1 and DGAT2 enzymes analyzed by western blotting in MCF-7 and 4T1 cells transfected with a control or Elov15-targeting siRNA. **C** Determination of total fatty acid content in stable or transient Elov15-depleted MCF-7 cells. Data are expressed as the mean \pm SD of three independent experiments. $**P < 0.01$ and $***P < 0.001$ were determined by a Student's *t* test. **D** Analysis of triacylglycerol content in Elov15-silenced MCF-7 or 4T1 cells treated with siRNA targeting Elov15 or a control siRNA. Data are expressed as the mean \pm SD of three independent experiments. $***P < 0.001$ was determined by a Student's *t* test. **E**, **F** Determination of total fatty acid content by GC-MS (**E**) and triacylglycerol content by enzymatic assay (**F**) in tumors from MMTV-PyMT;Elov15^{+/+} (Elov15^{+/+}; *n* = 5) and MMTV-PyMT;Elov15^{-/-} (Elov15^{-/-}; *n* = 5). Data are expressed as the mean \pm SEM. $**P < 0.01$ was determined by Student's *t* test. **G** Analysis of triacylglycerol content in patient breast cancer subtypes (T) and paired non-tumoral breast (NT) tissues. $**P < 0.01$ was determined according to the Wilcoxon test. **H** Lipid-droplet staining with Bodipy 493/503 in 4T1 and MCF-7 cells transfected with siRNA targeting Elov15 or a control siRNA (ctrl). Histograms are average of the lipid-droplet number per cell. Data are expressed as the mean \pm SD of three independent experiments. $****P < 0.0001$ was determined by a Student's *t* test. Scale bar: 20 μ m. **I** Amount of total fatty acids in lipid droplets purified from control MCF-7 cells or with stable Elov15 depletion. Data are expressed as the mean \pm SD of three independent experiments. $*P < 0.05$ were determined by Student's *t* test. **J** Oil Red O lipid-droplet staining in mammary tumors of MMTV-PyMT;Elov15^{+/+} (Elov15^{+/+}; *n* = 10) and MMTV-PyMT;Elov15^{-/-} (Elov15^{-/-}; *n* = 13) mice. Data represent the percentage of positive-stained tumor cells with $*P < 0.05$ determined by a Mann-Whitney test. **K** Lipid-droplet quantification by fluorescence microscopy after Bodipy490/503 staining in Elov15-depleted MCF-7 in the presence or absence of DGAT inhibitors. Histograms show the average number of lipid droplets per cell and error bars represent the mean \pm SD of three independent experiments with $****P < 0.0001$ according to one-way ANOVA analysis with Tukey's test. Scale bar: 20 μ m.

Bodipy 493/503 staining

Cells on coverslips were fixed with 4% paraformaldehyde (PFA) for 10 min at RT and incubated with 10 μ M of Bodipy 493/503 (ThermoFisher Scientific) solution for 30 min. After washing, coverslips were mounted with ProlongTM diamond antifade mountant (Molecular Probes) containing 20 μ M Hoechst (ThermoFisher Scientific). The detection of lipid droplets using Bodipy 493/503 was carried out using 470-nm excitation and 525-nm emission wavelengths. The staining was observed with Axio Imager 2 (Carl Zeiss Microscopy GmbH, Jena, Germany) connected to an Apotome 2 module (Carl Zeiss GmbH). Images were taken with a AxioCam MRm monochrome CCD camera (Carl Zeiss GmbH). The lipid-droplet number was determined by assessing the number of total lipid droplets and the cell number (minimum 100 cells per experimental condition) in the field for the calculation of the average lipid-droplet number per cell. In addition, a quantification of the average fluorescence intensity per cell was performed in the randomly recorded fields using imageJ software.

Oil Red O staining

Mouse mammary tumors were collected in Optimal Cutting Temperature compound (OCT) (ThermoFisher Scientific) and placed on dry ice. The OCT tumor samples were fixed with 4% PFA for 10 min at RT. The fixed OCT sections were stained with 0.3% Oil Red O solution for 30 min. After washing, the tumor sections were stained with hematoxylin and mounted with an aqueous mounting solution.

The score of lipid droplets in tumors was performed using QuPath 0.2.3 software [50] after scanning the slides with a Nanozoomer using the NDP.view scan software. Data are presented as the percentage of positive lipid-droplet cancer cells over total breast cancer cells in the tumoral zone.

Phalloidin staining

Cells on coverslips were washed with cold PBS and fixed with 4% PFA for 10 min at RT. After cell permeabilization with 0.1% v/v Triton X-100 (Euromedex) in PBS, cells were incubated with FITC-Phalloidin (50 μ g/ml) for 40 min. After washing with PBS, cells were mounted with ProlongTM diamond antifade mountant (Molecular Probes) containing 20 μ M Hoechst (ThermoFisher Scientific) and observed with Axio Imager 2 (Carl Zeiss Microscopy GmbH, Jena, Germany) connected to an Apotome 2 module (Carl Zeiss GmbH). Images were taken with an AxioCam MRm monochrome CCD camera (Carl Zeiss GmbH). The quantification of cellular morphology modification was based on the ratio between the number of cells with an epithelial-like morphology and the number of cells with a mesenchymal-like morphology in the recorded fields.

Immunofluorescence staining of TGF- β receptors

For fluorescence microscopy analysis, cells were grown and treated on coverslips, washed with PBS, and fixed with 4% PFA for 10 min. Cells were permeabilized with 0.2% saponin (Sigma-Aldrich) in PBS and saturated with 3% BSA in PBS for 20 min at RT. Cells were incubated with a primary antibody against TGF- β R1 (PA5-3871; Invitrogen) overnight at 4°C in 3% BSA in PBS. Samples were incubated with an Alexa568-conjugated anti-rabbit antibody (Invitrogen) for 30 min at RT in 3% BSA in PBS. Coverslips were mounted with ProlongTM diamond antifade

mountant (Molecular Probes) containing 20 μ M Hoechst (ThermoFisher Scientific) and observed with Axio Imager 2 (Carl Zeiss Microscopy GmbH, Jena, Germany) connected to an Apotome 2 module (Carl Zeiss GmbH). Images were taken with AxioCam MRm monochrome CCD camera (Carl Zeiss GmbH).

For flow cytometry analysis, cells were washed in cold PBS and collected by scraping, then saturated with 10% FBS in PBS for 10 min. After a washing step, cells were stained for 40 min on ice with an isotype control IgG-PE (Biolegend), or an anti-mouse TGF- β R2-PE (R&D Systems) or an anti-human TGF- β R2-PE (Biolegend). Flow cytometry analysis was performed with a BD LSR II flow cytometer (BD Biosciences). For TGF- β R1 staining, human and mouse cells were incubated with anti-TGF- β R1 (Merck Millipore) for 40 min on ice, and after a washing step, cells were incubated with an isotype control Alexa568-conjugated IgG or a secondary Alexa568-conjugated anti-rabbit antibody (Invitrogen) for 20 min at RT. Cells were washed and collected in PBS for analysis on an LSR Fortessa cytometer and the BD FACSDiva software (BD Biosciences). Data were analyzed using the FlowJo software (Tree Star, USA) and presented in the mean of fluorescence intensity.

RNA extraction and RT-qPCR

Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed with an iScript cDNA Synthesis Kit (Bio-Rad). PCR was performed using Powerup SYBR Green master mix (Applied Biosystems, Life Technologies) on StepOnePlus™ Real-Time PCR System (Applied Biosystems). Relative gene expression was calculated using $\Delta\Delta C_t$ values. Target mRNA levels were normalized to β -actin mRNA and 18 S RNA. Primers (Supplementary Table S5) were purchased from Life technologies.

Cell proliferation assay


Cells were washed with PBS and fixed with 100% cold ethanol. Coloration with 4% crystal violet in 10% methanol was carried out to visualize adherent cells. After washing with water, crystal violet was dissolved in 33% acetic acid for OD quantification on a TECAN spectrophotometer at 540 nm.

Colony-formation assay

Cells were plated at low density (150 4T1 cells and 200 MCF-7 cells/well) in six-well plates. The culture medium was renewed every 3 days. Cells were fixed and stained with crystal violet for counting of colonies after 1 week for 4T1 cells and 3 weeks for MCF-7 cells. Data were presented as an average of total counted colonies per well.

Oxygen consumption rate

The analysis of the real-time Oxygen Consumption Rate was performed in Elov15-downregulated expression MCF-7 cells (4×10^4 cells/well) with a Seahorse XFe96 Extracellular Flux Analyzer (Agilent Technologies). The measure under basal conditions and with the sequential addition of respiratory chain complex inhibitors (Mito Stress assay [oligomycin, FCCP, antimycin A/rotenone]; Agilent Technologies) were carried out in DMEM-based medium (without glucose, pyruvate and L-glutamine) according to the manufacturer's instructions. OCR data were normalized per μ g of protein per well.



Western blotting

Cells were lysed in RIPA supplemented with protease (#P8340; Sigma-Aldrich) and phosphatase (#P5726; Sigma-Aldrich) inhibitors. Protein lysates in Laemmli loading buffer were boiled for 5 min at 95 °C and separated by SDS-PAGE electrophoresis. Proteins were wet-transferred onto nitrocellulose membranes (AmershamTM ProtranTM 0.45-μm

NC; Amersham). Membranes were saturated with 5% w/v non-fat milk or 5% BSA in TBST (Tris-buffered saline plus 0.1% Tween 20) for 1 h at RT. Primary antibodies (listed in Supplementary Table S6) were diluted in the appropriated saturation solutions for overnight incubation at 4 °C. After TBST washes, membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000^{eme}; Cell Signaling

Fig. 6 Lipid droplets mediate the dependent expression of TGF- β receptors in Elov15-silenced breast cancer cells. **A, B** Analysis of TGF β -1 and 2 receptor expression in MCF-7 cells by flow cytometry. MCF-7 cells with stable shRNA or siRNA silencing of Elov15 expression were treated for 48 h with DGAT1 and 2 inhibitors and collected for anti-TGF β -R1 and TGF β -R2 staining. Values are fold change of mean fluorescence intensities (MFI) relative to MCF-7 cells treated with vehicle (DMSO) and control shRNA or siRNA (ctrl). Histograms and error bars are expressed as the mean \pm SD of at least three independent experiments. **C, D** Analysis of TGFBR1 and TGFBR2 mRNA expression in MCF-7 cells. MCF-7 cells with stable shRNA or transient siRNA silencing of Elov15 expression were treated for 48 h with DGAT1 and 2 inhibitors. Values used are fold changes of Elov15 mRNA expression relative to MCF-7 cells treated with vehicle (DMSO) and control shRNA or siRNA (ctrl). Histograms and error bars are expressed as the mean \pm SD of three independent experiments. **E** Quantification of acetyl-CoA in Elov15-silenced MCF-7 cells using an siRNA or shRNA and treated with DGAT1 and DGAT2 inhibitors. Histograms and error bars represent the mean \pm SD of five independent experiments. **F** Level of Smad2 acetylation in low Elov15 expressing (shRNA Elov15) and control (shRNA ctrl) MCF-7 cells. A sample of siRNA Smad2-treated MCF-7 cells was used as control of Smad2 silencing. Images are representative of two independent experiments. **G** Analysis of Smad2 acetylation in shRNA control and shRNA Elov15 MCF-7 treated with DGAT1 inhibitor. Images are representative of two independent experiments. **H** Analysis of TGFBR1 and TGFBR2 mRNA expression at 48 h by RT-qPCR in Elov15-targeting shRNA and control shRNA MCF-7 cells treated by siRNA ctrl or against smad2. Values are the fold change relative to shRNA control MCF-7 cells transfected with siRNA control. Histograms and error bars represent the mean \pm SD of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 and non-significant (ns) were determined by one-way ANOVA analysis with Tukey's test (**A, B, C, D, E, H**).

Technologies). Membranes were imaged using Enhanced Chemi Luminescence (ClarityTM Western ECL Substrate; Bio-Rad) in a sChemiDocTM XRS⁺ imaging system (Biorad). Images were analyzed with Image Lab 5.1 software (Biorad, France).

Co-immunoprecipitation

Cells were lysed in non-denaturing lysis buffer (20 mM Tris HCl pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA and 1% Triton X-100) supplemented with protease (#P8340; Sigma-Aldrich) and phosphatase (#P5726; Sigma-Aldrich) inhibitors. Pre-clearing step of 1 mg cell lysates were performed with 5 μ g rabbit IgG (#02-6102; ThermoFisher Scientific) and 20 μ l Pierce Protein A/G Magnetic beads (#88802; ThermoFisher Scientific) on a rotating shaker for 1 h and 30 min, at 4 °C. The lysates were then incubated overnight at 4 °C with 5 μ g of rabbit IgG or anti-acetylated lysine (#9441; Cell Signaling Technology). The immunoprecipitated proteins were collected after 1 h 30 incubation with 20 μ l Pierce Protein A/G Magnetic beads (4 °C), followed by the elution with 50 μ l of Elution buffer (0.1 M Glycine, pH 2.0) and neutralization with a buffer containing 1 M Tris HCl, pH 8.0. Samples were added 1 \times Laemmli loading buffer β -mercaptoethanol-free, without heating, and separated by SDS-PAGE electrophoresis. As described above, western blotting was performed using anti-Smad2 antibody (#5339; Cell Signaling Technology; 1:1000).

Invasion assay

Cell invasion assay was carried out in Transwell insert (Greiner Bio-One) with a Matrigel-coated 8- μ m pore membrane (#356237; Corning). Cells in culture medium with 0.1% FBS were placed on top of the Matrigel-coated inserts, and complete culture medium (10% FBS) was added in the lower chamber. After 48 h, cells were fixed with 4% PFA and stained with a crystal violet solution (Sigma-Aldrich) for 30 min. The inserts were washed to remove non-invasive cells. Images of randomly selected fields were recorded by an AxioScope A1 microscope (ZEISS Microscopy) coupled camera (Jenoptik; GRYPHAX NAOS) using the GRYPHAX software. Cell counting was performed using ImageJ software.

Immunohistochemistry analysis

Paraffin-embedded tumor breast tissue samples from breast cancer patients with or without metastasis were deparaffinized and rehydrated. Tissue sections were saturated with peroxidase blocking buffer and incubated with a primary antibody against ELOVL5 (#HPA047752; Sigma-Aldrich) for 1 h. After washing, HRP polymer-conjugated secondary antibodies (K4002; Dako) were then incubated with the tissue sections for 20 min followed by a 5-min coloration with 1 g/ml of DM827-3, 3'-diaminobenzidine (DAB). Hematoxylin and eosin staining was used to visualize nuclei. Tissue sections were mounted with an organic mounting solution from Dako. Quantification of ELOVL5 staining was analyzed with QuPath 0.2.3 [50] after slides were scanned by Nanozoomer controlled by NDP.view scan software (Hamamatsu). Data are presented as the average H-score of ELOVL5 expression in each slide comparing tumor and adjacent non-tumoral tissues.

For Ki67 staining, the protocol is as above using a primary antibody against Ki67 (#MIB-1 clone; Agilent) and an anti-mouse HRP polymer-

conjugated secondary antibody (K4000; Dako). The H-score correlations between ELOVL5 and Ki67 are demonstrated by comparing the tumoral matching zones of the same patient.

MMTV-PyMT and Elov15 mice

Mice were bred and maintained in the animal facility of the University of Burgundy according to the center instructions, all the experiments were carried out following the instructions of the Federation of European Animal Science Associations. Experimental designs involving animals were approved by the Ethics Committee of the University of Burgundy (projects #17461, #14557 and #22358). *Elov15*^{-/-} C57BL/6N mice were obtained from the Mutant Mouse Regional Resource Center at UC Davis (Davis, CA) and were generated by inserting a genetrap cassette in the exon 3 of the *Elov15* gene. B6.FVB-Tg (MMTV-PyMT)634Mul/LelJ (MMTV-PyMT) mice were obtained from the Jackson Laboratory. Male MMTV-PyMT mice were crossed with female *Elov15*^{-/-} to obtain MMTV-PyMT;*Elov15*^{+/-} mice. Then, experimental female mice were obtained by crossing male MMTV-PyMT;*Elov15*^{+/-} mice with female *Elov15*^{+/-} mice. Mouse genotyping was performed using extraction solution (E7526; Sigma-Aldrich) and neutralization solution B (N3910; Sigma-Aldrich) and with PCR primer sets (Supplementary Table S5) for the detection of MMTV-PyMT transgene and *Elov15* invalidation. Female mice were monitored by palpation and tumor growth measured every 2 days. Tumor surface (mm²) were calculated by multiplying the measured length and width of the tumor. Upon reaching 180 days of age, mice were sacrificed, and tissues (lung and tumors) were collected for analysis.


Mammary gland grafting and tail vein injection

4T1 cells (0.5 \times 10⁶ cells in 100 μ l PBS per mice) were injected into the inguinal mammary fat pad of 8-week-old mice (BALB/cByJ; Charles River) using a 26Gx7/8" needle and 1 ml syringe. Tumors were measured three times per week and tumor size (mm²) was calculated by multiplying the measured length and width of the tumor. On the 23rd day post injection, mice were sacrificed, and tumors and lungs were collected for downstream experiments.

For tail vein injection of MCF-7 cells, female 8-week-old nude mice (NMR1; Charles River) were pre-treated with β -estradiol (Sigma-Aldrich) at 4 μ g/100 μ l PBS/mice by intraperitoneal injection 24 and 48 h before cell injection. *Elov15* knockdown and control MCF-7 cells (5 \times 10⁶ cells in 100 μ l PBS per mice) were injected into the tail vein using insulin syringes (30 G \times 1/2"). Injection with β -estradiol were carried out three times/week. Mice were sacrificed 35 days after MCF-7 cell injection, and lungs were collected for metastatic quantification.

For tail vein injection of 4T1 cells, 1 \times 10⁵ 4T1 cells in 50 μ l PBS per mice were injected into the tail vein of 8-week-old mice (BALB/cByJ; Charles River) by using insulin syringes (30 G \times 1/2"). The mice were sacrificed 11 days post-cell injection and lungs were collected for metastase analysis.

Lungs were fixed in formalin and paraffin-embedded. Tissues were dewaxed and rehydrated for hematoxylin and eosin staining. Tissue sections were then mounted with an organic mounting solution. Scoring the invasive tumoral area over the total lung area was performed using QuPath 0.2.3 software after scanning the slides with a Nanozoomer using the NDP.view scan software (Hamamatsu). Data are presented as the ratio of total tumor area over the total lung area.



Patients and METABRIC datasets

Research on patient samples was conducted in agreement with the Declaration of Helsinki and approved by the Ethics Committee of the Centre Georges-François Leclerc, University Hospital François Mitterrand Dijon-Bourgogne (Dijon, France), and the Burgundy Advisory Committee for the

Protection of People in Biomedical Research. The patient's informed consent was obtained before project enrollment. The clinical and pathological characteristics of patients are summarized in Supplementary Tables 2–4.

Discovery Metabric datasets, generated by the Molecular Taxonomy of Breast Cancer International Consortium, was used as a public dataset.

Fig. 7 Elov15 loss-induced lipid droplets enhance EMT, cell invasion, and lung metastasis. **A** Expression of EMT markers analyzed by western blotting in Elov15-depleted MCF-7 cells using an shRNA or siRNA treated with vehicle (DMSO) or DGAT inhibitors (DGAT1i and DGAT2i) for 48 h. Images are representative of two independent experiments. **B** Expression of EMT marker mRNA (VIM, vimentin; CDH1, cadherin-1, and OCLN, occludin) analyzed by RT-qPCR in Elov15-silenced MCF-7 cells treated with vehicle (DMSO) or DGAT inhibitors (DGAT1i and DGAT2i) for 48 h. Data are expressed as the mean \pm SD of three independent experiments. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$ and non-significant (ns) were determined by one-way ANOVA analysis with Tukey's test. **C, D** Analysis of cell invasion through a Matrigel-coated membrane for Elov15-depleted MCF-7 (**C**) or 4T1 (**D**) breast cancer cells treated with DGAT inhibitors (DGAT1i and DGAT2i) relative to their respective breast cancer cells treated with a control shRNA or siRNA (ctrl) and vehicle (DMSO). Data are the mean \pm SD of three independent experiments with $**P < 0.01$ and $****P < 0.0001$ determined by one-way ANOVA analysis with Tukey's test. Representative images are shown. **E** QuPath analysis for quantification of lung surface with metastases in female NMRI-nude mice with tail vein injection of shRNA Elov15 or shRNA control (ctrl) MCF-7 cells. DGAT1 inhibitor (10 μ M) was loaded in MCF-7 cells 24 h before injection. Lungs were collected 35 days post injection. Data represent the mean \pm SEM with $*P < 0.05$, $**P < 0.01$ and $***P < 0.001$ determined by Kruskal-Wallis analysis with a Dunn's multiple comparison test. Representative images are shown.




Fig. 8 Schematic illustration depicting the role of Elov15 in the regulation of breast tumor growth and metastasis. A downregulation of Elov15 expression induced a lipogenic program (decrease of p-ACC expression and increase of Scd1 expression) supporting an increase of fatty acid content. In addition, the loss of Elov15 expression activated the DGAT1/2 expression and the synthesis of triacylglycerols (TAG) resulting in a lipid-droplet accumulation. The content of Acetyl-CoA increased in a DGAT1/2-dependent manner triggering the acetylation of Smad2 which upregulated the expression of TGF- β receptors 1 and 2. The activation of TGF- β receptors contributed to the repression of cell proliferation and to the induction of metastatic properties (EMT and invasion).

Normalized data, obtained with the Illumina HT 12 platform, were requested, and downloaded from the European Genome-phenome Archive (EGA) under the identifiers EGAD00010000210 and EGAD00010000211. Overall survival and molecular classification were available.

Statistical analysis

Statistical analyses were performed with the GraphPad Prism 9.1 software. After verifying data for normal distribution and variance, we applied one of the following statistical tests: Mann-Whitney test, Student's *t* test or one-way ANOVA. *P* values were determined as statistically significant with $*P < 0.05$; $**P < 0.01$; $***P < 0.001$; $****P < 0.0001$. Data are presented as mean \pm SD or SEM.

DATA AVAILABILITY

The data generated or analyzed during this study are available from the corresponding author upon request.

REFERENCES

1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. *Int J Cancer*. 2021;149: 778–89.
2. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. *Lancet Glob Health*. 2020;8:e1027–37.

3. Ji P, Gong Y, Jin ML, Hu X, Di GH, Shao ZM. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017. *Front Oncol.* 2020;10:650.
4. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. *N Engl J Med.* 2006;355:560–9.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature.* 2000;406:747–52.
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA.* 2001;98:10869–74.
7. Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, et al. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. *Breast.* 2020;52:50–57.
8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020;70:7–30.
9. Wang Z, Wang DH, Park HG, Yan Y, Goykhman Y, Lawrence P, et al. Identification of genes mediating branched chain fatty acid elongation. *FEBS Lett.* 2019;593:1807–17.
10. Cardoso F, Spence D, Mertz S, Corneliusen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). *Breast.* 2018;39:131–8.
11. Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. *Sci Rep.* 2017;7:45411.
12. Yang J, Antin P, Bex G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol.* 2020;21:341–52.
13. Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmüller S, Seppänen-Laakso T, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. *Cancer Res.* 2011;71:3236–45.
14. Li J, Dong L, Wei D, Wang X, Zhang S, Li H. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells. *Int J Biol Sci.* 2014;10:171–80.
15. Rios Garcia M, Steinbauer B, Srivastava K, Singhal M, Mattijssen F, Maida A, et al. Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence. *Cell Metab.* 2017;26:842–855.e845.
16. Stoiber K, Naglo O, Pernpeintner C, Zhang S, Koeberle A, Ulrich M, et al. Targeting de novo lipogenesis as a novel approach in anti-cancer therapy. *Br J Cancer.* 2018;118:43–51.
17. Pascual G, Avgustinova A, Mejetta S, Martín M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. *Nature.* 2017;541:41–45.
18. Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu X, et al. Exogenous lipids promote the growth of breast cancer cells via CD36. *Oncol Rep.* 2017;38:2105–15.
19. Yamashita Y, Nishiumi S, Kono S, Takao S, Azuma T, Yoshida M. Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer. *BMC Cancer.* 2017;17:589.
20. Leonard AE, Bobik EG, Dorado J, Kroeger PE, Chuang LT, Thurmond JM, et al. Cloning of a human cDNA encoding a novel enzyme involved in the elongation of long-chain polyunsaturated fatty acids. *Biochem J.* 2000;350:765–70.
21. Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. *Cancer Res.* 2021;81:1704–18.
22. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. *Am J Pathol.* 2003;163:2113–26.
23. Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? *Cancer Med.* 2019;8:5574–6.
24. Cruz ALS, Barreto EA, Fazolini NPB, Viola JPB, Bozza PT. Lipid droplets: platforms with multiple functions in cancer hallmarks. *Cell Death Dis.* 2020;11:105.
25. David CJ, Massagué J. Contextual determinants of TGF β action in development, immunity and cancer. *Nat Rev Mol Cell Biol.* 2018;19:419–35.
26. Wang G, Yin T. Rapamycin enhances the antiproliferative effect of transforming growth factor- β on MCF-7 human breast cancer cells. *Exp Ther Med.* 2017;14:748–52.
27. Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, et al. TGF- β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. *Mol Oncol.* 2018;12:305–21.
28. Al Ameri W, Ahmed I, Al-Dasim FM, Ali Mohamoud Y, Al-Azwani IK, Malek JA, et al. Cell type-specific TGF- β mediated EMT in 3D and 2D models and its reversal by TGF- β receptor kinase inhibitor in ovarian cancer cell lines. *Int J Mol Sci.* 2019;20:3568.
29. Huang Y, Chen Z, Lu T, Bi G, Li M, Liang J, et al. HIF-1 α switches the functionality of TGF- β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer. *J Exp Clin Cancer Res.* 2021;40:398.
30. Soukupova J, Malfettone A, Bertran E, Hernández-Alvarez MI, Peñuelas-Haro I, Dituri F, et al. Epithelial-mesenchymal transition (EMT) induced by TGF- β in hepatocellular carcinoma cells reprograms lipid metabolism. *Int J Mol Sci.* 2021;22:5543.
31. Liu S, Ren J, Ten Dijke P. Targeting TGF β signal transduction for cancer therapy. *Signal Transduct Target Ther.* 2021;6:8.
32. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, et al. Focal irradiation and systemic TGF β blockade in metastatic breast cancer. *Clin Cancer Res.* 2018;24:2493–504.
33. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. *Oncogene.* 2005;24:39–46.
34. Liang Y, Han H, Liu L, Duan Y, Yang X, Ma C, et al. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. *Oncogenesis.* 2018;7:98.
35. Balaban S, Lee LS, Varney B, Aishah A, Gao Q, Shearer RF, et al. Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis. *Mol Oncol.* 2018;12:1623–38.
36. Jun B, Mukherjee PK, Asatryan A, Kautzmann MA, Heap J, Gordon WC, et al. Elovans are novel cell-specific lipid mediators necessary for neuroprotective signaling for photoreceptor cell integrity. *Sci Rep.* 2017;7:5279.
37. Rugolo F, Bazan NG, Calandria J, Jun B, Raschella G, Melino G, et al. The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome. *Oncogene.* 2021;40:5741–51.
38. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, et al. Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. *Clin Cancer Res.* 2016;22:5337–48.
39. Jin C, Yuan P. Implications of lipid droplets in lung cancer: associations with drug resistance. *Oncol Lett.* 2020;20:2091–104.
40. Nardi F, Fitchew P, Brooks KM, Franco OE, Cheng K, Hayward SW, et al. Lipid droplet velocity is a microenvironmental sensor of aggressive tumors regulated by V-ATPase and PEDF. *Lab Invest.* 2019;99:1822–34.
41. Li Z, Liu H, Luo X. Lipid droplet and its implication in cancer progression. *Am J Cancer Res.* 2020;10:4112–22.
42. Abramczyk H, Surmacki J, Kopeć M, Olejnik AK, Lubecka-Pietruszewska K, Fabianowska-Majewska K. The role of lipid droplets and adipocytes in cancer. Raman imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to adipocytes in cancerous human breast tissue. *Analyst.* 2015;140:2224–35.
43. Antalis CJ, Uchida A, Buhman KK, Siddiqui RA. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. *Clin Exp Metastasis.* 2011;28:733–41.
44. Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander Linden C, et al. TGF β 2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. *Nat Commun.* 2020;11:454.
45. Xu S, Chen T, Dong L, Li T, Xue H, Gao B, et al. Fatty acid synthase promotes breast cancer metastasis by mediating changes in fatty acid metabolism. *Oncol Lett.* 2021;21:27.
46. Petan T, Jarc E, Jusović M. Lipid droplets in cancer: guardians of fat in a stressful world. *Molecules.* 2018;23:1941.
47. Englinger B, Laemmerer A, Moser P, Kallus S, Röhr C, Pirker C, et al. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. *Int J Cancer.* 2020;147:1680–93.
48. Hultsch S, Kankainen M, Paavola L, Kovanen RM, Ikonen E, Kangaspeka S, et al. Association of tamoxifen resistance and lipid reprogramming in breast cancer. *BMC Cancer.* 2018;18:850.
49. Schlaepfer IR, Hitz CA, Gijón MA, Bergman BC, Eckel RH, Jacobsen BM. Progesterone modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. *Mol Cell Endocrinol.* 2012;363:111–21.
50. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. *Sci Rep.* 2017;7:16878.

ACKNOWLEDGEMENTS

The present work was supported by the “Ligue Régionale contre le Cancer comité Grand-Est” and by a French Government grant managed by the French National Research Agency under the program “Investissements d’Avenir”, referenced ANR-11-LABX-0021 (Lipstic Labex). The authors would like to thank the lipidomic, CELLIMAP and flow cytometry platforms, and the animal facility of the Université de Bourgogne. The authors are very grateful to Lil Proukhitzky for metabolic experiments, Julie Maréchal from the Centre de Ressources Biologiques Ferdinand Cabanne CHU Dijon for providing breast cancer tissues, and Dr. Ronan Quéré for providing molecular tools.

AUTHOR CONTRIBUTIONS

TLVK designed and conducted all experiments, analyzed the data, and wrote the manuscript; LP conducted in vitro experiments; VD performed IHC experiments; SP conducted in vivo experiments; CT performed METABRIC analysis; AJ, EG, AD, EL, TJ, and LD helped for methodology; JPPdB supervised the lipidomic experiments; SC helped for writing; LG, Laurent Arnould, and Lionel Apetoh provided human samples and MMTV-PyMT mouse model; CT performed metabolic analysis and discussed the data; CR, DM, and FG discussed the data; MR conceived the study, analyzed the data, wrote the manuscript, and supervised the project.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-022-05209-6>.

Correspondence and requests for materials should be addressed to Mickaël Rialland.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022